Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
ÌÇÐÄ´«Ã½
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE Geyer, C. E., Huang, C., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Fischer, H. H., Redondo, A., Jackisch, C., Jacot, W., Conlin, A. K., Schneeweiss, A., Wapnir, I. L., Fasching, P. A., DiGiovanna, M. P., Wuelfing, P., Arce-Salinas, C., Crown, J. P., Shao, Z., Caremoli, E., Wu, H., Lam, L. H., Tesarowski, D., Smitt, M., Douthwaite, H., Singel, S. M., von Minckwitz, G. AMER ASSOC CANCER RESEARCH. 2019View details for
View details for